ATXS

Astria Therapeutics (ATXS)

Astria Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ATXS

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/02/15	08 : 13	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ATXS	Astria Therapeutics Inc
2025/02/15	05 : 45	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ATXS	Astria Therapeutics Inc
2025/02/05	06 : 10	Business Wire	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ATXS	Astria Therapeutics Inc
2025/02/04	22 : 00	Business Wire	Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference	NASDAQ:ATXS	Astria Therapeutics Inc
2025/02/03	22 : 00	Business Wire	Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session	NASDAQ:ATXS	Astria Therapeutics Inc
2025/01/23	22 : 00	Business Wire	Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis	NASDAQ:ATXS	Astria Therapeutics Inc
2025/01/13	22 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATXS	Astria Therapeutics Inc
2025/01/13	22 : 00	Business Wire	Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE	NASDAQ:ATXS	Astria Therapeutics Inc
2025/01/07	21 : 45	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ATXS	Astria Therapeutics Inc
2025/01/04	06 : 10	Business Wire	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ATXS	Astria Therapeutics Inc
2024/12/20	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATXS	Astria Therapeutics Inc
2024/12/11	22 : 00	Business Wire	Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE	NASDAQ:ATXS	Astria Therapeutics Inc
2024/12/04	06 : 10	Business Wire	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/15	07 : 45	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/15	06 : 15	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/15	02 : 03	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/14	06 : 21	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/14	06 : 10	Business Wire	Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/14	06 : 01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/13	22 : 00	Business Wire	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/09	04 : 17	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ATXS	Astria Therapeutics Inc
2024/11/05	06 : 10	Business Wire	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ATXS	Astria Therapeutics Inc
2024/10/30	21 : 00	Business Wire	Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting	NASDAQ:ATXS	Astria Therapeutics Inc
2024/10/21	21 : 00	Business Wire	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	NASDAQ:ATXS	Astria Therapeutics Inc
2024/10/16	21 : 00	Business Wire	European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema	NASDAQ:ATXS	Astria Therapeutics Inc
2024/10/03	05 : 10	Business Wire	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ATXS	Astria Therapeutics Inc
2024/09/30	21 : 00	Business Wire	Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema	NASDAQ:ATXS	Astria Therapeutics Inc
2024/09/27	21 : 00	Business Wire	Astria Therapeutics to Present at Upcoming Global Angioedema Forum	NASDAQ:ATXS	Astria Therapeutics Inc
2024/09/19	21 : 00	Business Wire	Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress	NASDAQ:ATXS	Astria Therapeutics Inc
2024/09/05	05 : 10	Business Wire	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ATXS	Astria Therapeutics Inc